Effects of galcanezumab on migraine severity and symptoms: post hoc analysis of Phase 3 trials

Takeaway

  • In people with episodic and chronic migraine, galcanezumab treatment reduces the number of monthly migraine days, the severity of migraine, and the symptoms associated with migraine compared with placebo.

Why this matters

  • Migraine is a leading cause of disability worldwide and is associated with symptoms such as nausea, vomiting, photophobia, and phonophobia.

  • Galcanezumab is a monoclonal antibody targeting the calcitonin gene-related peptide that is approved to treat migraine; however, limited data are available from Phase 3 studies that describe how galcanezumab impacts the severity and symptoms of migraine.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.